Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SELP | P16109 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25542963 | 1.00 | FAAH (0.64) | FAAHHSP90AA1L3MBTL1CNR2DNM1 | |
| SCHEMBL7113945 | 1.00 | FAAH (0.64) | FAAHHSP90AA1L3MBTL1CNR2DNM1 | |
| SCHEMBL1535042 | 1.00 | FAAH (0.64) | FAAHHSP90AA1L3MBTL1CNR2DNM1 | |
| SCHEMBL16234563 | 1.00 | FAAH (0.64) | FAAHHSP90AA1L3MBTL1CNR2DNM1 | |
| SCHEMBL10226131 | 1.00 | FAAH (0.64) | FAAHHSP90AA1L3MBTL1CNR2DNM1 | |
| SCHEMBL19521439 | 1.00 | FAAH (0.64) | FAAHHSP90AA1L3MBTL1CNR2DNM1 | |
| SCHEMBL7105382 | 1.00 | FAAH (0.64) | FAAHHSP90AA1L3MBTL1CNR2DNM1 | |
| SCHEMBL1449527 | 0.98 | FAAH (0.61) | FAAHHSP90AA1L3MBTL1CNR2DNM1 | |
| SCHEMBL12362917 | 0.92 | CNR2 (0.52) | FAAHHSP90AA1L3MBTL1CNR2DNM1 | |
| SCHEMBL10021727 | 0.92 | FAAH (0.50) | FAAHHSP90AA1L3MBTL1CNR2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3220741-B1 | COMPOSITION AND KITS FOR INHIBITION OF PATHOGENIC MICROBIAL INFECTION AND METHODS OF USING THE SAME | ROCHAL IND LLC (US) | 2021-02-24 | — | — | EP | claimed |
| EP-2138189-B1 | Synergistic microbicidal compositions | ROHM & HAAS (US) | 2013-02-13 | — | — | EP | claimed |
| EP-1076554-B1 | CLEAR PERSONAL CARE FORMULATIONS CONTAINING QUATERNARY AMMONIUM COMPOUNDS AND OTHER NITROGEN-CONTAINING COMPOUNDS | GOLDSCHMIDT CHEMICAL COMPANY (US) | 2004-10-13 | — | — | EP | claimed |
| US-11952434-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230101323-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-30 | — | — | US | disclosed |
| CN-114652813-A | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| CN-107108698-B | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3778622-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3218392-B1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200216498-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-09 | — | — | US | disclosed |
| US-10633419-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-9856292-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3218392-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160137696-A1 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-19 | — | — | US | disclosed |
| WO-2016077518-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| EP-2015635-A2 | SYNERGISTICALLY ENHANCED DISINFECTING SOLUTIONS | S.K. Pharmaceuticals Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007136558-A3 | SYNERGISTICALLY ENHANCED DISINFECTING SOLUTIONS | KARAGOEZIAN HAMAPR (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007136558-A2 | SYNERGISTICALLY ENHANCED DISINFECTING SOLUTIONS | S.K. PHARMACEUTICAL, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952434-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | FAAH 4282/4885HSP90AA1 410/4885L3MBTL1 1391/4885 |
| US-20160137696-A1 | Immunomodulators | CD74, ICOS, HAVCR2 | FAAH 4282/4885HSP90AA1 410/4885L3MBTL1 1391/4885 |
| US-20230101323-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | FAAH 4282/4885HSP90AA1 410/4885L3MBTL1 1391/4885 |
| US-10633419-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | FAAH 4282/4885HSP90AA1 410/4885L3MBTL1 1391/4885 |
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | FAAH 4282/4885HSP90AA1 410/4885L3MBTL1 1391/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | FAAH 4282/4885HSP90AA1 410/4885L3MBTL1 1391/4885 |
| US-20200216498-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | FAAH 4282/4885HSP90AA1 410/4885L3MBTL1 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.